Evommune (EVMN) files for proposed NYSE IPO

Evommune (EVMN) has filed for a proposed NYSE IPO.

The company describes itself as: "Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States."

Morgan Stanley, Leerink Partners, Evercore ISI, and Cantor will serve as underwriters.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Jefferson Capital (JCAP) PT Raised to $28 at Citizens on Above Forecast Purchase Volume
• Kepler Cheuvreux Upgrades Komax Holding AG (KOMN:SW) to Buy